Insmed Inc (INSM)vsMarker Therapeutics Inc (MRKR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MRKR
Marker Therapeutics Inc
$1.34
+6.35%
HEALTHCARE · Cap: $16.95M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 12816% more annual revenue ($606.42M vs $4.70M). MRKR leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MRKR
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -110.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MRKR
The strongest argument for MRKR centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MRKR
The primary concerns for MRKR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while MRKR is a value play — different risk/reward profiles.
MRKR carries more volatility with a beta of 1.45 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
INSM generates stronger free cash flow (-294M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Marker Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?